PBYI Share Price

Open 38.15 Change Price %
High 40.25 1 Day 1.95 5.13
Low 37.35 1 Week 2.80 7.54
Close 39.95 1 Month 0.70 1.78
Volume 1276337 1 Year 7.43 22.85
52 Week High 73.27
52 Week Low 0.00
PBYI Important Levels
Resistance 2 42.64
Resistance 1 41.53
Pivot 39.18
Support 1 38.37
Support 2 37.26
NYSE USA Most Active Stocks
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
SE 40.68 -0.78%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
BAC 23.65 -1.00%
BAC 23.65 -1.00%
BAC 23.65 -1.00%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
FNP 35.24 12.02%
FNP 35.24 12.02%
MTL 5.76 11.63%
MTL 5.76 11.63%
CVI 21.96 11.53%
HF 31.88 11.51%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Puma Biotechnology Inc (NYSE: PBYI)

PBYI Technical Analysis 1.5
As on 27th Apr 2017 PBYI Share Price closed @ 39.95 and we RECOMMEND Sell for LONG-TERM with Stoploss of 41.81 & Buy for SHORT-TERM with Stoploss of 37.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
PBYI Target for April
1st Target up-side 46.19
2nd Target up-side 52.49
3rd Target up-side 58.79
1st Target down-side 28.21
2nd Target down-side 21.91
3rd Target down-side 15.61
PBYI Other Details
Segment EQ
Market Capital 620310592.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.pumabiotechnology.com
PBYI Address
PBYI
10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
Phone: 424-248-6500
Fax: 424-248-6501
Interactive Technical Analysis Chart Puma Biotechnology Inc ( PBYI NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Puma Biotechnology Inc
PBYI Business Profile
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products to enhance cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.